HCM
RANI icon

Heights Capital Management’s Rani Therapeutics RANI Stock Holding History

Heights Capital Management’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$711K Buy
+934,580
New +$829K 0.16% 134

Other funds holding RANI

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Heights Capital Management's RANI Position: Q2 2026 in Review

Heights Capital Management opened a new position in Rani Therapeutics (RANI) in Q2 2026: 934,580 shares worth $711K. The stake represents 0.16% of the portfolio and ranks #134 among its holdings.

67 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

  • Heights Capital Management held 934,580 shares of Rani Therapeutics worth $711K as of Q2 2026.
  • Rani Therapeutics was a new Heights Capital Management position in Q2 2026.
  • Rani Therapeutics made up 0.16% of Heights Capital Management's portfolio in Q2 2026, its #134 holding.
  • 67 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on Heights Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.